Single‐pill amlodipine besylate/atorvastatin calcium (Caduet^®, Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS). The benefits of lowering blood pressure (BP) in patients with HTN and lowering cholesterol in patients with DYS are well known and well studied. However, worldwide, many patients with HTN have concomitant DYS, which places them at greater risk for cardiovascular disease compared with patients with just one of these risk factors. Clinical trials have demonstrated that amlodipine plus atorvastatin can be safely co‐administered across the dose range. Single‐pill amlodipine/atorvastatin reduces both BP and cholesterol and may help to improve the management of patients with concomitant HTN and DYS.